368 related articles for article (PubMed ID: 23053396)
1. Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.
Soong L; Henard CA; Melby PC
Semin Immunopathol; 2012 Nov; 34(6):735-51. PubMed ID: 23053396
[TBL] [Abstract][Full Text] [Related]
2. Cytokines in the immunity and immunopathogenesis in leishmaniases.
Saha B; Silvestre R
Cytokine; 2021 Sep; 145():155320. PubMed ID: 33127260
[TBL] [Abstract][Full Text] [Related]
3. The Paradox of a Phagosomal Lifestyle: How Innate Host Cell-
Carneiro MB; Peters NC
Front Immunol; 2021; 12():728848. PubMed ID: 34557194
[TBL] [Abstract][Full Text] [Related]
4. Immunopathogenesis of infection with the visceralizing Leishmania species.
Wilson ME; Jeronimo SM; Pearson RD
Microb Pathog; 2005 Apr; 38(4):147-60. PubMed ID: 15797810
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-producing T cell subsets in human leishmaniasis.
Kemp K
Arch Immunol Ther Exp (Warsz); 2000; 48(3):173-6. PubMed ID: 10912621
[TBL] [Abstract][Full Text] [Related]
6. The importance of T cell-derived cytokines in post-kala-azar dermal leishmaniasis.
Jafarzadeh A; Jafarzadeh S; Sharifi I; Aminizadeh N; Nozari P; Nemati M
Cytokine; 2021 Nov; 147():155321. PubMed ID: 33039255
[TBL] [Abstract][Full Text] [Related]
7. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
Zijlstra EE
PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
[TBL] [Abstract][Full Text] [Related]
8. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
[TBL] [Abstract][Full Text] [Related]
9. An Insight Into Systemic Immune Response in
Thakur L; Madaan P; Jain A; Shankar V; Negi A; Chauhan SB; Sundar S; Singh OP; Jain M
Front Immunol; 2021; 12():765684. PubMed ID: 35087516
[TBL] [Abstract][Full Text] [Related]
10. Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function through Inhibitory Receptor Expression.
Medina-Colorado AA; Osorio EY; Saldarriaga OA; Travi BL; Kong F; Spratt H; Soong L; Melby PC
PLoS One; 2017; 12(1):e0169496. PubMed ID: 28103263
[TBL] [Abstract][Full Text] [Related]
11. Chemokines in host-parasite interactions in leishmaniasis.
Teixeira MJ; Teixeira CR; Andrade BB; Barral-Netto M; Barral A
Trends Parasitol; 2006 Jan; 22(1):32-40. PubMed ID: 16310413
[TBL] [Abstract][Full Text] [Related]
12. Conundrums in leishmaniasis.
Saha B; Bhattacharjee S; Sarkar A; Bhor R; Pai K; Bodhale N
Cytokine; 2021 Sep; 145():155304. PubMed ID: 33004260
[TBL] [Abstract][Full Text] [Related]
13. The F1F3 Recombinant Chimera of
Alves-Silva MV; Nico D; de Luca PM; Palatnik de-Sousa CB
Front Immunol; 2019; 10():724. PubMed ID: 31024556
[No Abstract] [Full Text] [Related]
14. Animal models for the analysis of immune responses to leishmaniasis.
Sacks DL; Melby PC
Curr Protoc Immunol; 2015 Feb; 108():19.2.1-19.2.24. PubMed ID: 25640990
[TBL] [Abstract][Full Text] [Related]
15. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis.
Kemp M; Kurtzhals JA; Bendtzen K; Poulsen LK; Hansen MB; Koech DK; Kharazmi A; Theander TG
Infect Immun; 1993 Mar; 61(3):1069-73. PubMed ID: 8432588
[TBL] [Abstract][Full Text] [Related]
16. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?
McMahon-Pratt D; Alexander J
Immunol Rev; 2004 Oct; 201():206-24. PubMed ID: 15361243
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals a Broad Splenic Inflammatory Environment that Conditions Macrophages toward a Disease-Promoting Phenotype.
Kong F; Saldarriaga OA; Spratt H; Osorio EY; Travi BL; Luxon BA; Melby PC
PLoS Pathog; 2017 Jan; 13(1):e1006165. PubMed ID: 28141856
[TBL] [Abstract][Full Text] [Related]
18. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
Rostan O; Gangneux JP; Piquet-Pellorce C; Manuel C; McKenzie AN; Guiguen C; Samson M; Robert-Gangneux F
mBio; 2013 Sep; 4(5):e00383-13. PubMed ID: 24045639
[TBL] [Abstract][Full Text] [Related]
19. Imaging host-Leishmania interactions: significance in visceral leishmaniasis.
Forestier CL
Parasite Immunol; 2013; 35(9-10):256-66. PubMed ID: 23772814
[TBL] [Abstract][Full Text] [Related]
20. Immunoregulation in human American leishmaniasis: balancing pathology and protection.
Gollob KJ; Viana AG; Dutra WO
Parasite Immunol; 2014 Aug; 36(8):367-76. PubMed ID: 24471648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
